Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$20.91 ▲ +0.26
(+1.26%)
MKT CAP: $1.24B • VOL: 968.3K
52W L $7 52W H $26
ROARABLE / RQD
D- • 37/100
PIOTROSKI
2 / 9
VOR // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$371.6M | -$121.2M | -$126.0M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$696.0M | -$116.9M | -$117.9M |
| EBITDA (Normalized) | -$370.9M | -$121.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$142.7M | -$99.7M | -$100.3M |
| Capital Expenditures (CapEx) | $941.0K | $229.0K | — |
| Free Cash Flow (FCF) | -$143.7M | -$99.9M | -$100.3M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $396.5M | $81.9M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | -$164.3M | $96.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR VOR.